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Abstract

TP53 as a Biomarker in Head and Neck Squamous Cell Carcinoma
Thomas J. Ow, MD
Supervisory Professor: Jeffrey N. Myers, MD, PhD

Currently, there are no molecular biomarkers that guide treatment decisions
for patients with head and neck squamous cell carcinoma (HNSCC).

Several

retrospective studies have evaluated TP53 in HNSCC, and results have suggested
that specific mutations are associated with poor outcome. However, there exists
heterogeneity among these studies in the site and stage of disease of the patients
reviewed, the treatments rendered, and methods of evaluating TP53 mutation.
Thus, it remains unclear as to which patients and in which clinical settings TP53
mutation is most useful in predicting treatment failure.
In the current study, we reviewed the records of a cohort of patients with
advanced, resectable HNSCC who received surgery and post-operative radiation
(PORT) and had DNA isolated from fresh tumor tissue obtained at the time of
surgery. TP53 mutations were identified using Sanger sequencing of exons 2-11
and the associated splice regions of the TP53 gene. We have found that the group
of patients with either non-disruptive or disruptive TP53 mutations had decreased
overall survival, disease-free survival, and an increased rate of distant metastasis.
When examined as an independent factor, disruptive mutation was strongly
associated with the development of distant metastasis.

v

As a second aim of this project, we performed a pilot study examining the
utility of the AmpliChip® p53 test as a practical method for TP53 sequencing in the
clinical setting. AmpliChip® testing and Sanger sequencing was performed on a
separate cohort of patients with HNSCC. Our study demonstrated the ablity of the
AmpliChip® to call TP53 mutation from a single formalin-fixed paraffin-embedded
slide. The results from AmpliChip® testing were identical with the Sanger method
in 11 of 19 cases, with a higher rate of mutation calls using the AmpliChip® test.
TP53 mutation is a potential prognostic biomarker among patients with
advanced, resectable HNSCC treated with surgery and PORT.

Whether this

subgroup of patients could benefit from the addition of concurrent or induction
chemotherapy remains to be evaluated in prospective clinical trials. Our pilot study
of the p53 AmpliChip® suggests this could be a practical and reliable method of
TP53 analysis in the clinical setting.
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Introduction

The Clinical Challenges of Head and Neck Squamous Cell Carcinoma
Squamous cell carcinoma of the head and neck (HNSCC) ranks among the
top ten cancers worldwide for both incidence and mortality, with over 600,000 new
cases diagnosed and over 300,000 estimated deaths each year(1). Approximately
45,000 new cases of HNSCC were diagnosed, with approximately 8,000 deaths
occurring in the United States during 2010(2).

Head and neck squamous cell

carcinoma (HNSCC) can arise anywhere in the upper aerodigestive tract,
particularly in the oral cavity, larynx, and pharynx.
The treatment options for HNSCC primarily include surgical resection,
external beam radiation, and the use of chemotherapy(3, 4), most commonly
platinum-based cytotoxic regimens(5, 6) or the EGFR inhibitor, cetuximab(7, 8).
The strategies are largely chosen based on site of disease and staging according to
the AJCC TNM criteria(9). In general, surgical resection is used as the primary
modality to treat squamous carcinomas of the oral cavity due to the increased
morbidity

of

definitive

radiation

to

this

region,

particularly

the

risk

of

osteoradionecrosis of the mandible (10). Organ-sparing protocols, with radiation as
the primary modality, are typically recommended for pharyngeal and laryngeal
squamous cancers(6).

Definitive treatment of advanced-stage disease (AJCC

Stage III and IV) requires multimodality approaches, generally surgical resection
with post-operative radiation (PORT), or concurrent chemoradiation (CCR) for
organ-sparing

approaches

(3,

4,

6).
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Several

studies

have

evaluated

induction/neoadjuvant chemotherapeutic strategies for the treatment of stage III and
IV HNSCC(5, 6, 11, 12), further adding to the complexity of treatment options under
consideration for the patient with advanced HNSCC, though the indications and
measurable benefit from these strategies remain to be further delineated.
In 2004, two multi-institutional, phase-III randomized controlled trials
evaluated the efficacy of adding concomitant cisplatin to PORT for advanced,
resectable HNSCC, and each independently supported the use of post-operative
chemoradiation (POCRT) in this setting(13, 14).

When considering these two

studies together, it became clear that patients with extracapsular spread of lymph
node disease (ECE) and those with positive surgical margins after surgical
resection represented a high-risk group for recurrence and mortality, and these
factors are now strong indications for POCRT(15).
Figure-1 summarizes the current approach to treating patients with HNSCC
based on the guidelines detailed above.

Figure-1 – Algorithm summarizing the current approach to the treatment of HNSCC.
*in specific cases (eg. laryngeal microsurgery for T1 glottic cancer)
**in specific cases (eg. advanced T4 laryngeal cancer)
Please note that the management of an individual patient with HNSCC is much more complex, with
multiple considerations dependent on disease site, stage, and patient factors. The algorithm is presented
here to highlight key factors that play a role in determining the treatment regimen of a typical patient, and is
not meant to provide treatment guidelines to be used in the management of patients in the clinical setting.
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This is a simplified view of the decision tree for the clinical team for the typical
patient with HNSCC, but the algorithm highlights the important factors leading to the
multidisciplinary treatment strategy of this disease.

Two principles are evident

regarding the management of HNSCC. First, multimodality strategies are crucial to
increase the likelihood of control of advanced disease, and these options become
more

complicated

as

disease

stage

increases.

Second,

contemporary

management decisions remain largely founded upon disease site, stage, and
additional clinical and pathologic factors.
Despite the multitude of treatment options available to treat HNSCC, many
patients continue to suffer from the morbidity of treatment, treatment failure, disease
recurrence, and the development of metastasis. The recurrence and survival rates
vary greatly depending on disease site in the head and neck.

For example,

outcomes with early stage tumors of the glottic larynx can be quite favorable with 5year disease-free rates as high as 80 – 90%(16), whereas treatment of early-stage
oral tongue cancer can have local failure rates as high as 30-50%(17). Patients
with advanced, resectable head and neck squamous cell carcinoma, even after
POCRT (the most rigorous strategy available), are faced with progression-free
survival rates in the range of 50-60%(13, 14). As described above, the treatment
decisions for patients with HNSCC are made based upon disease site and stage,
and it is evident that these clinicopathologic considerations are limited in their ability
to accurately predict the outcome of patients with specific treatments. Futhermore,
the unacceptable but consistent failure rate, even for early-stage lesions in some
cases, suggest that additional factors are necessary to aid our ability to predict
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which HNSCC tumors will be best managed with either simple or more
comprehensive treatments selecting from surgery, radiation, or our growing number
of chemotherapeutic options. To this end, there is currently a paucity of molecular
biomarkers that are employed today to guide the management of HNSCC. A single,
yet notable exception that has been elucidated in recent years is the presence of
HPV infection and/or p16 expression in oropharyngeal cancer.
Recent data has identified an increasing incidence of patients diagnosed with
oropharyngeal squamous cell carcinoma (18-20), and this disease appears to be
increasing most among middle-aged, white male patients who are non-smokers(19,
21, 22). Epidemiology studies have established that the human papilloma virus
(HPV), particularly the high-risk serotypes 16 and 18 (22), are present at a high rate
in tumor specimens of these patients.
retrospective

evidence

that

the

There is substantial prospective and

subgroup

of

patients

with

HPV-positive

oropharyngeal cancer has a more favorable prognosis as compared to patients with
oropharynx cancer that is negative for HPV(21, 23). Active HPV infection results in
several alterations in key cell signaling pathways that promote tumorigenesis. In
particular, expression of the E6 and E7 viral proteins lead to the inactivation of two
key tumor suppressors, p53 and Rb, along with several other key factors in DNA
damage signaling and cell cycle regulation(24).

The ensuing dysregulation of

normal cell cycle regulation and inhibition of feedback loop mechanisms lead to
overexpression of p16, and recent studies have shown that p16 overexpression is
also associated with improved outcome in HNSCC (21, 22). P16 overexpression is
certainly a surrogate for active HPV infection in tumor cells, and there are reports
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supporting p16 overexpression as a prognostic marker independent of HPV, but this
remains to be further clarified(21, 22).

Evaluation of HPV infection and/or p16

overexpression have become prognostic biomarkers in the workup of oropharyngeal
squamous carcinoma(21, 23). HPV appears to play a much less significant role in
other sites of HNSCC, and the overall utility of HPV as a biomarker in these
subsites is still being explored (25-27). Thus, molecular biomarkers that can be
used for prognosis and for guiding management decisions are lacking for HPVnegative oropharyngeal carcinomas as well as for other sites of HNSCC.
HPV and p16 have become prognostic biomarkers for patients with
oropharyngeal squamous cell carcinoma, and the current outstanding question is if
patients with HPV-positive oropharynx cancer can receive a de-escalated treatment
regimen (eg. lower total dose of radiation, or withholding concurrent chemotherapy)
without decreasing disease control and survival, thus potentially making this the first
biologic marker used to alter management decisions that would otherwise proceed
based on site and stage alone.
Despite the advances in our understanding of HPV in oropharyngeal cancer,
there are still no biomarkers currently used to assist with clinical decision-making in
the treatment of patients with HNSCC, leaving the clinician to rely strictly upon
clinicopathologic factors to determine treatment for HPV-negative oropharynx
cancer, and HNSCC from other anatomic sites. There is a need for biomarkers that
identify those patients with HNSCC that could benefit from additional treatment, and
the current study aims to explore the potential utility of TP53 mutation in this role.
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Description of the TP53 gene and p53 tumor suppressor
TP53 is the most frequently mutated gene in human cancer(28-30), and has
been well-studied since its first description over 30 years ago (31).

P53 was

determined to be a tumor suppressor roughly 10 years after its discovery(32, 33),
and since that time alteration of p53 has been shown to play a key role in the
pathogenesis and progression of numerous, if not all human cancers.

P53 is

involved in coordinating the response to cell stressors such as DNA damage,
hypoxia, and oncogenic stress(34). P53 functions largely as a sequence-specific
transcription factor with hundreds of targets in the human genome(35). Described
targets include genes that induce cell cycle arrest (eg. p21, GADD45), activate DNA
repair mechanisms (eg. p48, XPC), and drive apoptosis (eg. Bax, Apaf1, Noxa)(35,
36). P53 also has cytoplasmic and mitochondrial targets that regulate apoptosis,
autophagy, and metabolism(36).

Because radiation therapy and cytotoxic

chemotherapeutic agents act through many of these same pathways, p53 also
plays an important role in the response to these cancer therapies(37, 38).

In

summary, p53 responds to many stressors that promote carcinogenesis, and it
protects against the development of malignancy by guiding the cell either toward a
state of repair or self-destruction.

A summary of p53 function and results of

mutation are summarized in Figure-2.
The myriad functions of p53 can be attributed to its complicated structure and
regulation. P53 is a protein made up of 393 amino acids encoded by 11 exons
found in the TP53 gene on chromosome 17(39, 40).

The protein product is

composed of several domains, including a DNA-binding domain, an oligomerization
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region, and a tetramerization site(39) (see Figure-3, results section). At the latter

*

Figure 2. Summary of p53 function and consequences of TP53 mutation.
(*Model of mutant p53 shows codon sites where mutations were found in the current study)

region, p53 forms a dimer with another p53 molecule, which in turn combines with a
second p53 dimer to form the final functional complex(39). Under basal conditions,
p53 is maintained at a very low level secondary to regulation by MDM2, which
directly binds and ubiquitinates p53, resulting in proteosomal degradation of the
p53 protein(34). Cell stressors generally cause p53 stabilization via inhibition of
MDM2 degradation.

For example, ATM, a protein activated by DNA damage,

phosphorylates p53, stabilizing the molecule and inhibiting MDM2-mediated
degradation(34). This archetypal model of p53 regulation is just one example of
p53 regulation. There are several amino acids of the p53 protein that are targets of
enzymatic modification, which include phosphorylation, ubiquitination, neddylation,
sumoylation, acetylation, and methylation. These sites are found in every domain of
the p53 protein, including the transactivation domain, the DNA-binding region, and
the tetramerization site(41).

In addition to enzymatic modification, there are
7

additional levels of regulation of the p53 molecule and its function (eg. alternative
splicing, regulation by microRNA, etc.), however a full discussion of these
processes is beyond the scope of this report.

Each alteration in the molecular

structure of p53 may change its stability, its capacity to translocate to the nucleus,
or its influence on transcriptional and cytoplasmic targets.
In summary, the complexity of the TP53 gene and the p53 protein leads to its
diverse role in tumor biology, and the effects of mutation of TP53 are equally
complex.

Overview of TP53 mutation in Human Cancer
The patterns of mutations found in TP53 in human cancer have several
interesting and unique features. Whereas most tumor suppressor genes are altered
by truncating mutations or deletions, the mutation pattern of p53 is unique in that
there appears to be a strong selection bias for missense mutations, particularly
involving amino acids in the DNA-binding domain(29, 30, 42, 43). For this reason,
several studies of TP53 in HNSCC have relied on sequencing exons from this
region alone to assess for mutations in the TP53 gene(44, 45). Missense mutation
often leads to p53 stabilization and accumulation of p53 in tumor cells that can be
noted on immunohistochemical examination(46-48).
Mutation in p53 can be categorized as either ‘loss of function’ or ‘gain of
function’. If a mutation renders p53 expression absent, then all p53 function is lost.
However, mutant forms of p53 (especially those carrying missense mutations) often
retain their expression, and therefore may remain partially functional. Loss of p53

8

function may also occur secondary to a dominant negative effect (DNE) by mutant
p53. DNE occurs when mutant p53 directly inhibits the remaining wild-type p53
produced by the normal allele.

Mutant p53 can also exhibit new, oncogenic

properties that are not attributable to the loss of p53 alone. These ‘gain-of-function’
mutations were first identified in 1991(49) and later definitively confirmed in
1993(50) through in vivo mouse studies in which B-cell tumors that were p53-null
became significantly more aggressive after mutant forms of p53 were introduced.
Since that time, many examples of p53 gain-of-function mutations have been
identified(51). The varying sequelae of mutation in TP53 are summarized above in
Figure-2.
It should be noted that mutation is not the only mechanism for p53
inactivation. P53 can be inactivated by tumor-associated viral proteins, as in the
abrogation of p53 by the HPV E6 protein, as described above. MDM2 amplification
is another well described mechanism of disruption of the p53 axis described in
human cancer (52), however MDM2 expression is more often diminished or lost in
HNSCC, and TP53 mutation predominates (53).
The 30-year history of p53 research has contributed significantly to our
understanding of this important protein, but the complexity of TP53 mutation has
limited the utility of this information in the clinical setting.

The role of TP53 mutation in HNSCC
TP53 mutation is very common in HNSCC, and cancer of the head and neck
ranks among breast, lung, and colorectal cancer as those in which TP53 mutations
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are most commonly found (IARC database version R15, (42)).

There are, of

course, several genetic alterations that consistently contribute to the development of
HNSCC.

Cyclin D1 or p16 overexpression, signaling through EGFR or MET,

SMAD4 mutation, PTEN loss, and PIK3CA activating mutations have all been noted
to contribute to the development of head and neck squamous cell carcinoma at a
relatively high frequency (54) . Two recent studies using whole exome sequencing
of HNSCC specimens have provided the most detailed examination of mutation in
this disease to date (55, 56).

Several mutations and gene alterations were

discovered and described, and interestingly both studies found frequent alterations
of NOTCH-1.

Additionally, as expected, TP53 mutations predominated in both

studies. Mutation in TP53 is present in 40 - 60% of reported cases of HNSCC (42,
44, 57, 58). Wild-type p53 is disrupted in an additional subset of HNSCC infected
by HPV, commonly found in tumors of the oropharynx, as described above. Similar
to other models of cancer progression(59), loss of heterozygosity of TP53 was
identified as an early event in the development of many head and neck cancers(58,
60), and mutations in TP53 have been associated with poor outcome in several
studies(44, 45, 57, 61).
In 1998, Koch, et al.(44) examined exons 5-9 of TP53 in tumors harvested
from 110 patients with HNSCC who received either primary radiation or adjuvant
radiation for treatment of their disease, and 48 (44%) were found to have a
mutation. Though not associated with decreased overall survival, TP53 mutation
was found to be associated with decreased progression-free survival, which
remained an independent factor after multivariate regression analysis. Erber et. al,
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in 1998(45), evaluated exons 5-8 of TP53 in tumors from 86 previously untreated
patients with HNSCC, and did not find a significant difference in overall survival
between the group with TP53 mutation versus the group with no mutation identified.
The authors did, however, classify TP53 mutation into structural and contact
mutations based on the location of the mutation in the L3, H2, S10, or Zinc binding
amino acids (contact mutations) proposed by Cho, et al(62) to make up the core
DNA-binding domain. They found that patients with TP53 contact mutations had
decreased overall and recurrence-free survival.

More recently, a large study

conducted by Poeta, et al. in 2007(57) evaluated TP53 in 420 patients with HNSCC
and classified mutations into disruptive (ie. nonsense mutations or missense
mutations in the L2-L3 region leading to an amino acid change with a different
polarity or charge) or nondisruptive (ie. all other non-conservative mutations). In
this study, representing the largest to date, TP53 mutation was associated with
decreased overall survival, and disruptive mutation was associated with the group
of patients with the poorest survival. After multivariate analysis, disruptive TP53
mutation remained strongly associated with decreased overall survival.

Most

recently, Lindenbergh, et al. in June, 2011(61) published a study evaluating 141
patients with HNSCC who either received surgery or surgery and radiation, and
found that truncating TP53 mutations were more strongly associated with poor
outcome than disruptive mutations.
There exists ample data to suggest that TP53 can be used to predict
outcome in HNSCC, however TP53 mutation in HNSCC tumors has not become
part of the routine evaluation in the clinical setting.
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Current limitations to TP53 as a biomarker in HNSCC
Despite several studies that have supported the potential of TP53 mutation
as a predictor of poor outcome in HNSCC, TP53 mutational analysis has not
become a routine diagnostic in the clinical setting.

There are currently several

limitations to the implementation of TP53 mutation analysis. One major limitation is
that previous studies have largely reviewed HNSCC patients with varying tumor
sites, disease stage, and treatments received(44, 45, 57, 61), and thus it is not clear
which group of patients would benefit most from the evaluation of TP53 mutation
analysis. Second, methods used to detect TP53 mutation have varied between
studies, as well, adding to the difficulty of arriving at generalizable conclusions from
a collective review of the literature(63). Finally, technical and economic limitations
have further hindered the implementation of TP53 mutation analysis in the clinical
setting. A more detailed review of these limitations is discussed in the following
sections.

Patients evaluated in studies examining TP53 in HNSCC have been
heterogeneous with regard to site, stage, and treatment. Several factors play a
role in the eventual outcome of patients with HNSCC, including disease site, stage,
HPV status, and the treatments that are provided.

The difficulty of arriving at

generalizable conclusions from the published literature studying p53 in HNSCC due
to these factors are well-summarized in the systematic review by Tandon(63).
Among the studies that have evaluated TP53 mutation and prognosis among
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patients with HNSCC, only a few have evaluated HPV status(61, 64), which is now
known to dramatically alter patient prognosis with current treatment stategies.
Furthermore, in the largest study to evaluate TP53, the patients examined received
a diverse array of treatments(57), and several other studies include at least two, if
not several treatment strategies among the patient cohorts(44, 45, 61). Therefore,
though TP53 mutation may be relevant to patients with HNSCC as a whole, it is
currently unclear for which patients TP53 mutation may be most useful in predicting
outcome or for guiding treatment decisions.

The method of detecting TP53 mutation has varied from study to study. There
are a multitude of methods for evaluating p53 in tumor specimens, most common of
which are immunohistochemical (IHC) evaluation for p53 protein expression (with a
vast array of potential antibodies) and direct sequencing of genomic DNA covering
either a subset or all of the exonic regions of TP53. Several of these methods have
been used in the published literature with varying results, making it difficult to arrive
at definitive conclusions from the available data(63). Because missense mutation in
TP53 often results in p53 overexpression, high p53 expression on IHC has been
used as a marker for TP53 mutation, and the majority of studies evaluating p53 in
HNSCC have used IHC to assess p53 status(63). The poor concordance between
TP53 mutation and IHC evaluation has been demonstrated(47).

Furthermore,

several studies have limited TP53 gene sequencing to a subset of TP53 exons
focusing on the DNA-binding domain(44, 45), whereas more recent studies have
evaluated the entire coding region of TP53(57, 61), perhaps leading to varying
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results or selection bias based on the mutations that were considered versus those
that were not.

The feasibility of sequencing DNA from HNSCC tumor samples has been
limited outside of the research setting.

Both technical and economical

considerations have limited the use of gene sequencing in the clinical setting. First,
standard processing of tissue samples involves formalin-fixation and paraffinembedding followed by staining for pathological review. Many patients are initially
identified at small, community-based hospitals and are subsequently referred to
multidisciplinary cancer centers for treatment. Furthermore, head and neck cancer
is commonly diagnosed from small biopsy samples, and a large fraction of patients
are never treated surgically. Techniques for sequencing large genomic regions
from formalin-fixed, paraffin-embedded tissue is limited, and PCR amplification is
often of poor quality or impossible due to DNA cross-linking and fragmentation
secondary to the embedding process. Therefore, current standard clinical practices
would require repeat acquisition of tumor for genetic analysis after initial diagnosis,
which would add increased and unnecessary risk to patients and additional, and
perhaps unnecessary medical costs. Furthermore, gene sequencing, until recently,
has been prohibitively expensive, and though costs have significantly decreased,
they remain substantial when considered for routine clinical practice. Finally, the
inherent and variable presence of normal tissue in biopsy samples can lead to falsenegative results when sequencing for mutations in a background of contaminating
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wildtype copies, which is yet another limitation to routine TP53 mutation detection
from biopsy samples.

Study Rationale, Hypothesis, and Aims
The evidence to date suggests that the TP53 gene is a potential prognostic
biomarker for patients with HNSCC, but the limitations highlighted above are
hurdles that must be overcome before TP53 mutation is deemed useful in the
clinical setting. There is a growing need to evaluate TP53 as a potential biomarker
in specific subsets of HNSCC patients, in particular patient groups in which current
standards of treatment are failing in a significant fraction, or those in which a
significant proportion of patients are at high risk of treatment-related morbidity yet
excellent outcomes are expected. Furthermore, techniques to evaluate TP53 in the
clinical setting must be rapid, reliable, and best performed on specimens that are
most readily available in the clinical setting- ie. formalin-fixed, paraffin-embedded
(FFPE) biopsy specimens. To further advance our knowledge of the utility of TP53
mutation as a clinical biomarker in HNSCC, we proposed the following hypothesis
and aims:

We hypothesize that TP53 mutation is associated with poor outcome in
patients with advanced, resectable HNSCC, and that TP53 mutation can be
reliably identified with the TP53 AmpliChip® test (Roche Molecular Systems®,
Pleasanton, CA) from tissue that is readily available from standard biopsy
specimens.
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Specific Aim #1:

To determine whether TP53 mutation could be used as a

predictor of poor outcome in advanced, resectable HNSCC treated with surgical
resection and post-operative radiation.

Before TP53 mutation can become clinically useful, it must be determined for which
subset of patients with HNSCC this potential biomarker would be most informative.
Patients with advanced, resectable disease are currently faced with the most
complex treatment options, many of which involve cytotoxic therapies (eg. radiation
and cisplatin) for which functional p53 would perhaps be the most relevant. We
also felt it was important to examine a cohort of patients who were all treated
similarly in order to determine the influence of TP53 status on outcome without the
added consideration of variability in treatments provided. In this study, we therefore
examined tumor samples from patients with advanced HNSCC who were uniformly
treated with surgery and PORT. If TP53 mutation could be used to predict poor
outcome among this cohort of patients, it would suggest that the presence of a
TP53 mutation may be an indication for the addition of chemotherapy to surgical
resection and PORT. We therefore sequenced the entire coding region of TP53
from the DNA from tumors among this cohort of patients using standard Sanger
sequencing, and patient records were reviewed in order to determine if the
outcomes of local-regional recurrence, metastasis, and death were associated with
mutation inTP53. Our intent was to examine TP53 mutation as a prognostic factor,
as well as to classify TP53 mutation into the nondisruptive and disruptive
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categories, as proposed by Poeta, et al.(57), in order to determine if these factors
were associated with poor outcome in our patient cohort.

Specific Aim#2: To assess the ability of the AmpliChip® TP53 test to identify TP53
mutation from formalin-fixed, paraffin-embedded specimens.

Previous studies have relied on sequencing from fresh frozen tissue enriched for
high tumor content with screening and/or microdissection. The availability of fresh
tissue for sequencing in the clinical setting, and the potential false-negative results
secondary to wild-type p53 contamination from surrounding or infiltrating normal
tissue often found in standard biopsy samples, remain two hurdles limiting the
routine use of TP53 mutation analysis.

Recent studies have evaluated a new

technology, the TP53 AmpliChip® (Roche Molecular Systems®, Pleasanton, CA) to
identify TP53 mutation in breast cancer and chronic lymphocytic leukemia(65, 66).
The AmpliChip® is a microarray-based technique that interrogates each nucleotide
in exons 2-11 of the TP53 coding regions and splice sites. The AmpliChip® is
therefore designed to detect single base-pair alterations only, and cannot detect
alterations ≥ 2 bases in size . DNA processing involves isolation, fragmentation,
PCR amplification, and labeling. The resulting processed DNA is then hybridized to
the microarray and scanned. These procedures overcome the limitations of poor
quality DNA in FFPE tissue, and the array is designed to detect the presence of
single nucleotide changes in the midst of a high wild-type sequence background.
We therefore designed a pilot study to assess the utility of the TP53 AmpliChip® to
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detect mutations in HNSCC samples. Formalin-fixed paraffin-embedded (FFPE)
specimens from 19 HNSCC samples were analyzed using this new technology and
results were compared to sequencing results obtained from the standard Sanger
technique perfomed on DNA isolated from corresponding fresh frozen tumor tissue.
The pilot study is designed to assess the ability of the AmpliChip® to identify TP53
mutations from a single slide of FFPE tissue, equivalent to a typical tissue sample
that would be available with current standard biopsy protocols for HNSCC.

The overall goal is to determine whether TP53 mutation can be evaluated with
a rapid, reliable method from paraffin-embedded biopsy samples, and also to
determine if TP53 mutation can be used to predict poor outcome among
patients with advanced, resectable HNSCC treated with surgery and PORT. In
achieving these aims we intend to further advance TP53 mutation as a
potential biomarker in HNSCC.
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Methods

Specific Aim #1:

To demonstrate that TP53 mutation is associated with poor

outcome in advanced, resectable HNSCC treated with surgical resection and postoperative radiation.

Patient Selection and Tissue Procurement
Patients evaluated and treated at The University of Texas MD Anderson
Cancer Center (UTMDACC) from 1992 – 2002 were recruited to participate in a
head and neck cancer tissue banking program under a protocol approved by the
institutional review board (IRB). Clinical records were reviewed retrospectively for
these patients and TP53 gene status was determined according to a second
protocol approved by the IRB at UTMDACC authorizing TP53 genomic analysis on
previously banked samples. All patients were previously untreated and received
primary treatment of squamous cell carcinoma of the oral cavity, pharynx, or larynx,
undergoing surgical resection followed by PORT. Specimens were harvested from
the tumor primary site and snap frozen at the time of surgery.
Patients who received neoadjuvant or adjuvant chemotherapy were
excluded. Frozen sections from all specimens were reviewed by a member of the
UTMDACC Pathology Department and were confirmed to be HNSCC with at least
70% of the specimen determined to be tumor. Clinical and pathologic factors were
recorded, including T stage, N stage, surgical margin status, extracapsular lymph
node extension (ECE), lymphovascular invasion (LVI), and perineural invasion
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(PNI). For the purposes of this study, pathology reports that did not explicitly
identify LVI or PNI were considered to be negative for these features. Additional
review of the pathology slides was performed if the original pathology reports did
not explicitly state the presence or absence of ECE or positive surgical margins.
Generally, all patients were evaluated every 2 - 3 months for the first year
following treatment, every 3 - 4 months the second year, and then every six months,
thereafter. The outcomes and dates of local recurrence (LR), local-regional
recurrence (LRR), development of distant metastasis (DM), disease-status at last
contact, and death were recorded.

DNA Extraction and Isolation
Approximately 10mg of tumor sample was minced and resuspended in pure
PBS. The sample then underwent overnight digestion with proteinase K at 55°C.
DNA was isolated using the QIAmp® DNA mini Kit (Qiagen®, Maryland, USA),
following the manufacturer’s protocol. Eluted DNA was quantified using the QuantItTM PicoGreen® system (Invitrogen®, Carlsbad, CA, USA).

TP53 Sequencing and Classification
The coding regions and surrounding splice sites from exons 2-11 of the TP53
gene were evaluated via direct sequencing from genomic DNA, which was sent to
Beckman Coulter Genomics (Beckman Coulter®, Brea, CA, USA).

Standard

Sanger sequencing using BigDye® Terminator chemistry (Applied Biosystems® Life
Technologies®, Carlsbad, CA, USA) was performed through the service provided
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by the company. TP53 point mutations were categorized as “disruptive” and “nondisruptive”.

Disruptive mutations were defined as stop codons, or missense

mutations occurring within the L2 or L3 loop of the key DNA-binding domain,
leading to substitution with an amino acid of a different polarity or charge group, as
described by Poeta, et al(57). All other point mutations, except for splice site and
insertion or deletion mutations (indels), were defined as non-disruptive mutations.
Splice site mutations and indels were classified together as a separate group, and
the disruptive and non-disruptive mutations were also categorized collectively as
“point mutations” for portions of the analysis.

In cases where more than one

mutation was identified and each mutation was classified into two different groups,
TP53 status was classified according to the mutation suspected to have the more
deleterious effect (eg. if a disruptive and a non-disruptive mutation were both
identified, then the tumor would be classified in the TP53 disruptive mutation
category).

Statistical Analysis
The proportion of TP53 mutations and disruptive TP53 mutations between
different groups of patients were compared using χ2 statistics, with or without Yates’
correction, or Fisher exact tests where appropriate. Each patient’s follow-up period
was defined as the date of surgery to the date of last contact or date of death.
Median follow –up time was calculated via the method of Schemper and Smith(67).
Overall survival was defined as the period from the date of completion of definitive
treatment to the date of death. Disease-free survival (DFS) was defined as the
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period from the date of completion of definitive treatment to the date of first
recurrence or date of death. Time to distant metastasis (DM) was defined as the
date of the completion of definitive treatment to the date of development of distant
metastasis. Patients who died prior to developing distant metastasis were censored
for analysis of this outcome.

Curves for overall survival (OS), DFS, and the

development of DM between TP53 mutant and wild-type groups, as well as
between disruptive, non-disruptive, and splice site/indels were estimated using the
Kaplan-Meier method, and Log Rank statistics were used to calculate the
significance of differences observed.

Univariate and multivariate proportional

hazards models were generated to identify prognostic factors that were significantly
associated with reduced OS, DFS, and DM. For all values, a threshold of p < 0.05
was accepted as statistically significant.

Specific Aim#2: To assess the ability of the TP53 AmpliChip® to identify TP53
mutation from formalin-fixed, paraffin-embedded specimens.

Tumor Specimens and Sample Preparation
Additional HNSCC tumor specimens were evaluated using both Sanger
sequencing of TP53 and using the AmpliChip® TP53 assay (Roche Molecular
Systems®, Pleasanton, CA). These samples were obtained from patients who had
consented to provide tumor specimens at the time of surgical resection, to be stored
as part of a Head and Neck Cancer tumor bank at UTMDACC, opened and
maintained under an active IRB approved protocol. An additional IRB-approved
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protocol was obtained authorizing TP53 genomic analysis. Fresh tissue was snap
frozen in liquid nitrogen at the time of acquisition and stored at -80 °C. Tissue
samples were deemed to be HNSCC after review by a pathologist at the time of
biopsy.
Each specimen was divided in half, with one half designated for Sanger
sequencing and the other half designated for TP53 AmpliChip® testing. For Sanger
sequencing, samples were embedded in Optimal Cutting Compound (OCT)
(Sakura®, Torrance, CA), frozen in dry ice conditions, and stored at -80 °C until
DNA isolation. For TP53 AmpliChip® analysis, specimens were fixed in formalin
and embedded in paraffin.

A representative slide was cut from this block and

stained with hematoxylin and eosin (H&E) stains. Each slide was reviewed by two
independent members of the laboratory (one postdoctoral fellow, and one research
instructor with formal pathology training) who graded each slide for percent tumor in
the entire specimen, and percent tumor composing the most dense region of each
sample- these two percentages were recorded and averaged to arrive at the final
call. The time from tissue acquisition to paraffin-embedding, acquisition to TP53
analysis, and from paraffin-embedding to TP53 analysis was recorded.

Patient Data
A retrospective chart review was performed under an IRB-approved protocol,
and the following data were recorded: date of diagnosis, date of surgical resection,
disease stage, primary or recurrent disease, treatments rendered, date of last
treatment of initial disease, date of last contact, presence or absence of LRR, the
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date LRR presented, presence or absence of the development of DM, date that DM
presented, date of last contact, and vital status.

DNA Isolation and TP53 Sequencing
For Sanger sequencing analysis, a cryotome was used to cut fifteen 10 uM
sections from the specimens previously embedded in OCT. From these sections,
the RecoverAllTM Total Nucleic Acid Isolation Kit (Ambion®, Applied Biosystems®,
Austin, Tx) was used per the manufacturer protocol to extract genomic DNA. The
amount of DNA isolated and the concentration was then analyzed using the
NanoDropTM 2000 (Thermo Fisher Scientific®, Wilmington, DE). DNA samples
were then sent to the Baylor College of Medicine Human Genome Sequencing
Center for sequencing of the coding regions and splice regions of TP53 for exons 211.

Sample Preparation for the AmpliChip® p53 Assay and Analysis
The DNA isolation, preparation, and analysis for the AmpliChip® p53 assay
are under development by Roche Molecular Systems® and not yet commercially
available. Paraffin-embedded slides were processed by Roche® under a research
agreement with our group. After formalin-fixation and paraffin embedding, one slide
was cut from each block for H&E staining, and a second 10um-thick section was cut
and mounted on a second slide. In cases of small samples, two or three sections
were mounted per slide. H&E slides were evaluated by two independent members
of the laboratory (one of whom is a pathologist by training) who provided an
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estimate of percent tumor of the entire sample and for the most dense regions of
tumor for each section. The estimates from the two evaluators were averaged to
arrive at the reported result.

Sections of most dense tumor were circled for

macrodissection. These slides were then sent to the Roche® laboratory, where
they were macrodissected and prepared for AmpliChip® testing as previously
reported (66, 68).
Briefly, slides were deparaffinized, DNA was extracted and isolated,
fragmented, PCR-amplified, biotin-labeled, and hybridized to the AmpliChip® p53
arrays. The arrays were then scanned using an Affymetrix® Dx2 Scanner and data
was analyzed to arrive at the TP53 sequence of each sample.

Statistical Analysis
Kaplan-Meier survival analysis for the patients was stratified by TP53 status,
and generated for each of the two TP53 analysis methods for comparative
purposes. This analysis was used to arrive at median disease-free survival for each
group.
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Results
Specific Aim #1:

To demonstrate that TP53 mutation is associated with poor

outcome in advanced, resectable HNSCC treated with surgical resection and postoperative radiation.

Patient characteristics and follow-up
We initially identified 88 patients that had received surgical resection and
PORT as treatment for HNSCC who had DNA available for this study.

Five

patients were excluded because their tumors arose in sites that the authors felt
were not appropriate for evaluation in this cohort (2 maxillary sinus, 1 lip, and 2 from
perioral skin), and five additional patients were excluded because they had received
neoadjuvant or adjuvant chemotherapy in addition to PORT as part of their
treatment regimen. A significant portion of the TP53 gene in 4 additional samples
could not be amplified and sequenced.

Therefore, a total of 74 patients were

evaluated in this study (Table-1).
The median age of the patients evaluated was 57 years (range 34 – 82).
There were 50 male and 24 female patients who had primary tumors from the oral
cavity (n=32), hypopharynx (n = 18), larynx (n = 16) or oropharynx (n=8). Sixty-five
patients were determined to have stage IV disease, 3 patients stage III, and only 6
patients stage I or II. Sixty-two patients (84%) presented with T3 or T4 tumors at
the primary site, and 46 (62%) had N2b or greater nodal burden at diagnosis.
Twenty-seven (36%) patients were noted on pathology to have PNI, and 17 (23%)
had signs of LVI. Forty-eight patients (65%) had ECE, and 13 (18%) had positive
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Table-1. Patients included and excluded, and TP53 mutations identified.
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margins after surgical resection. Table-2 summarizes the clinical and demographic
characteristics of the patients.
Table-2. Patient characteristics and distribution of TP53 mutations.

*Proportions of patients with TP53 mutation or disruptive mutation among patients with hypopharyngeal
primary tumors were compared to those arising from the other sites
**Patients with stage T1 or T2 disease were compared to those with stage T3 and T4 disease.
†Patients with stage N0 – N2a disease were compared to those with N2b or greater disease.
‡Patients with ECS or Positive surgical margins were compared to those who did not have these factors.
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The follow-up period for this group of patients ranged from 6.65 years to
22.20 years, with a median follow-up of 13.05 years. At the last review, 60 patients
had died (range of time to death, 32 days to 13.7 years; median overall survival was
2.73 years), 35 had no evidence of disease (NED) at last contact or death, 26 had
LRR or persistent disease, and 20 developed DM.

TP53 mutation and clinical-pathologic features
Forty-seven mutations in TP53 were identified in 43 patients (57%). There
were 18 disruptive, 18 non-disruptive mutations, 7 indel, and 4 splice site mutations.
The majority of missense mutations were within the DNA-binding domain (Figure-3),
with several located in known TP53 hotspot sites (eg. codons 175, 245, 273). A list
of the mutations identified is provided in Table-1.
TP53 mutations were found in tumors from 26 (63%) of the patients with T4
disease, 30 (65%) of the patients with N2b or greater disease, and 31 (65%) of
patients with ECE. The proportions of TP53 mutations and disruptive mutations
among the patients studied are presented in Table-2. Only hypopharyngeal primary
site was associated with a significantly increased proportion of TP53 mutations
(p=0.015), but the proportion of disruptive TP53 mutations did not appear enriched
in this group. There did appear to be a higher proportion of disruptive mutations
among the group of patients with either ECE or positive surgical margins, but this
difference did not reach statistical significance (p= 0.06). Among the 43 patients
with tumors harboring mutant TP53, 13 (30%) developed LRR, and 16 (37%)
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developed DM, compared to 12 (39%) and 6 (19%), respectively in the 31 patients
with p53 wildtype tumors. Twelve of 16 patients (75%) with tumors with disruptive
mutations developed relapse:

eight patients (50%) developed LRR, and eight

(50%) developed DM (4 of these patients developed both LRR and DM).

Figure-3. (A.) Frequency of point mutations in TP53. (B.) Proportions of patients
with mutation in TP53 and proportion of mutation types identified. * Indicates
position of disruptive mutations identified.
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Survival analysis and risk models
Univariate analysis showed that several clinico-pathologic factors were
associated with the endpoints of OS, DFS, and DM (Table-3). Stage T3 or T4
disease, N2b or greater nodal burden, and ECE and positive surgical margins were
significantly associated with reduced OS and DFS. N2b or greater nodal disease
was associated with DM.
Table-3. Univariate Analysis – factors associated with overall survival, disease-free survival,
and the development of distant metastasis.

*indicates significance of Log Rank p <0.05; Abbreviations: Neg Marg (negative surgical margins), Pos Marg
(positive surgical margins), ECE (extracapsular spread of regional disease), LVI (lymphovascular invasion), PNI
(perineural invasion), WT (wildtype TP53), WT-Other Mutations (wildtype T53, splice-site, insertion-deletion, and
non-disruptive mutations), WT-Splc-Indel (wildtype TP53, splice site, or insertion-deletion mutation)
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Kaplan-Meier survival estimates
showed that TP53 mutation was
associated with decreased DFS at
5 years (31.0% vs. 43.4%, p53
mutant group vs. the wild-type
p53 group, respectively, Log rank
p = 0.049) as shown in Figure-4.
When

TP53

mutations

were

classified into point mutations vs.
splice-site or indel mutations and
wildtype
were

p53,

point

associated

mutations

with

worse

outcomes for all three endpoints
(Figure-5;
Figure-4.
Overall (A.) and disease-free
survival (B.) for patients with HNSCC tumors
carrying wildtype TP53 versus mutant TP53.

Table-3).

Kaplan-

Meier plots displaying outcomes
after further division of TP53

point mutations into non-disruptive and disruptive mutations showed that the
patients with tumors bearing disruptive TP53 mutations had the worst outcome for
all three endpoints (Figure-6 and Figure-7). As an independent factor, disruptive
mutation was strongly associated with decreased DFS (HR 2.24, 95% CI 1.22 –
u4.12; Log Rank p = 0.03) and DM (HR 3.62, 95% CI 1.49 – 8.85, Log Rank p =
0.009).
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In multivariate analysis using Cox
proportional hazards models (Table-4),
Stage T3 or T4 disease remained a
significant factor associated with OS
and DFS, and N2b or greater disease
was associated with decreased OS
and DM.
remained

Point mutation in TP53
a

significant

factor

associated with poor outcome for all
three endpoints after adjustment for
other significant factors. When models
using

disruptive

mutation

were

examined, disruptive mutation was
strongly associated with DM (HR 4.0,
95%CI 1.61 – 9.90, p = 0.003).
Interestingly, the presence of positive
surgical margins and/or ECE were not
significant factors for any of the
multivariate models examining this
patient cohort.

Figure-5. Kaplan-Meier curves for
Overall survival (A.), disease-free survival (B.),
and distant metastasis (C.) for patients with
tumors carrying wildtype TP53, splice-site or
insertion/deletion (splice-indel) TP53 mutations,
or TP53 point mutations (defined as either
nondisruptive or disruptive).
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Figure-6. Overall (A.) and disease-free survival (B.) for patients with HNSCC tumors
carrying wildtype TP53, splice-site or insertion/deletion (splice-indel) TP53 mutations,
nondisruptive TP53 mutations, or disruptive TP53 mutations.

Figure-7. Distant metastasis in patients with tumors carrying wildtype TP53 vs. mutant
TP53 (A.) and in patients with tumors carrying wildtype TP53, splice-site or
insertion/deletion (splice-indel) TP53 mutations, nondisruptive TP53 mutations, or
disruptive TP53 mutation (B.).
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Table-4. Multivariate analysis- factors associated with overall survival, disease-free
survival, and distant metastasis. Two models were reviewed- one using p53 disruptive
mutation as a prognostic factor, and a second model using TP53 point mutation (combined
disruptive and –nondisruptive mutation vs. other patients) as a prognostic factor.

*indicates significance <0.05; Abbreviations: Pos Marg (positive surgical margins), ECE (extracapsular
spread of regional disease), NS = not a significant factor in the model, N/A = not applicable (no patients
with T1/T2 disease developed distant metastasis)

Specific Aim#2: To assess the ability of the
AmpliChip® p53 test to identify TP53 mutation from
formalin-fixed, paraffin-embedded specimens.

Patient Characteristics
Nineteen patients were evaluated with both TP53
AmpliChip® and Sanger Sequencing.

The median

follow-up for this group of patients was 28.16 months.
The majority of tumors (17 of 19) were from the oral
cavity.

Thirteen patients had a significant smoking

history and one patient had a history of chewing betel
quid.

The characteristics of this sample set are

summarized in Table-5.

Among these patients, 10

developed disease recurrence and 5 patients died during
the follow-up period.
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Table-5. Patient Characteristics

TP53 sequencing results
Sanger sequencing identified 12 mutations in 12 patients (41% of cohort). There
were 5 missense mutations, 4 nonsense mutations, 1 splice mutations, and 2
deletions using this sequencing technique. TP53 AmpliChip® results were obtained
from a single paraffin-embedded slide in all 19 cases. The average area of tumor
from which DNA was isolated was 28.14 mm2 (range 15 mm2 - 84 mm2), calculated
from the tumor area multiplied by the number of sections per slide. This method
identified 17 mutations in 15 patients (79% of cohort). There were twelve missense
mutations, 3 nonsense mutations, 1 splice mutation, and 1 deletion (frameshift)
mutation using the AmpliChip®. The two sequencing techniques agreed in 11 of 19
patients (58%). The AmpliChip® identified 5 missense, 3 nonsense, 1 splice site,
and 1 frameshift mutation (1bp deletion) that were also detected with Sanger
sequencing, and the AmpliChip® identified an additional 7 missense mutations.
The Sanger method identified 1 nonsense mutation and 1 two bp deletion that were
not detected with the AmpliChip®.

The two methods agreed upon 1 wildtype call.

These results are presented in Table-6.
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Table-6. Comparison of sequencing results of standard Sanger sequencing versus AmpliChip® p53 Test from HNSCC
specimens. Specimen characteristics provided.

Survival Analysis
Disease-free survival was calculated for the patient cohort comparing the
outcome in patients with wildtype TP53 to those with mutant TP53 as determined by
the two sequencing methods. When results from the Sanger sequencing method
were used to stratify patients, the median disease-free survival for the wildtype
TP53 group was 15.42 months, versus 33.03 months in the TP53 mutant group.
When the TP53 AmpliChip® was used, the median disease-free survival was 35.08
months in the TP53 wildtype group versus 33.02 months for the TP53 mutant group.
In both cases, a significant difference was not observed between the wildtype and
mutant groups when survival curves were compared using the Log Rank test (data
not shown).
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Discussion
Several reports have linked TP53 mutation to poor outcome in HNSCC. The
work by Poeta, et al. provides strong evidence that TP53 mutation, particularly
disruptive TP53 mutation, is associated with decreased overall and progression-free
survival(57). In their study, 131 patients received surgery alone and 203 patients
received additional treatment.

Seventy-eight patients received salvage surgical

resection, suggesting surgery was not the primary modality of treatment in at least
the majority of this subset. The variability in treatments provided to the patients in
this study makes it difficult to determine for which patients TP53 mutation is most
relevant. In addition, the pattern of relapse was not reported. An earlier study by
Erber, et al., classified TP53 mutation into contact mutations (those that disrupted
the core DNA-binding region) and structural mutations (those that alter the
conformation of p53), a system defined according to the crystal structure of the p53
molecule(62). TP53 contact mutations were associated with poor outcome among
86 patients with HNSCC(45). Sixty-six of 86 (77%) of the patients in this study
received PORT.

A similar paper by Koch, et al., examined 110 patients who

received either primary or adjuvant radiation therapy, and concluded that localregional failure was associated with mutation in TP53(44).

Most recently,

Lindenbergh, et al. evaluated TP53 mutation and HPV-status among 141 patients
with oral cavity or oropharyngeal squamous carcinoma who received either surgery
or surgery and radiation(61), and determined that truncating mutations (defined as
nonsense mutations, splice mutations, or frameshift mutations) were associated
with the poorest outcome. This group found that the truncation categorization was
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more discriminating than several other classification systems, including the
disruptive/nondisruptive system supported by Poeta, et al(57) and by our study.
The evidence to date has suggested that TP53 mutation may be a predictor for poor
outcome among patients treated with PORT, however, there is debate as to which
TP53 mutation classification system is most prognostic.
Our report is, to our knowledge, the first to focus on a group of HNSCC
patients with locally-advanced disease treated uniformly with surgery and PORT.
We have demonstrated that p53 point mutation is associated with decreased OS
and DFS.

In addition, thorough review of patterns of failure in our patient set

enabled us to detect that disruptive mutation was strongly associated with the
occurrence of distant metastasis.
Our study suggests that patients with HNSCC that carry TP53 point mutation,
especially disruptive mutations, may require additional treatment to PORT in order
to improve outcome. Multiple studies have shown the benefit of CCR for enhancing
local-regional control and OS in advanced HNSCC in both the adjuvant and
definitive treatment settings(6, 13, 14, 69). Similarly, induction chemotherapy may
significantly reduce the rate of distant metastasis(69, 70). Presently, the efficacy
and potential toxicity of induction chemotherapy followed by concomitant
chemoradiotherapy is under study for patients with regionally advanced
disease(71). More information is needed regarding the significance of TP53 as a
biomarker in patients undergoing sequential induction chemotherapy and radiation
or concomitant chemoradiotherapy. TP53 as a biomarker of virulent disease may
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become an important selection factor for patients being considered for treatment
with these combined therapeutic options.
Several studies have shown that HNSCC tumors that retain wild-type p53 are
more sensitive to cisplatin-based chemotherapy regimens, whereas loss of p53
function is associated with resistance to cisplatin(72-74). Studies in ovarian cancer
have shown that addition of taxane therapy to cisplatin can improve responses
among patients with tumors carrying a mutation in TP53(75, 76). A recent phase II
trial, RTOG 0024, reported promising results incorporating early post-operative
paclitaxel followed by concurrent paclitaxel-cisplatin with radiation in patients with
advanced, resectable HNSCC as compared to historical controls treated with
concurrent cisplatin alone and post-operative radiation(77).

Future prospective

trials incorporating evaluation of TP53 mutation are necessary to determine if
alternative drug regimens such as these can improve local-regional and distant
control in the setting of tumors with mutations in TP53 treated with surgery and
PORT.
Our study design did not aim at exploring the mechanism by which TP53
mutation affects tumor biology, thus we can only speculate as to why TP53 point
mutation and disruptive mutations were associated with poor outcome.

It is

possible that PORT had a reduced effect in patients whose tumors had TP53 point
mutations/disruptive mutations as compared to those with wild-type p53 or splicesite/indel mutations in our series.

P53 is known to be a key regulator of the

response to DNA damage, influencing several pathways leading to cell cycle arrest,
DNA repair, autophagy, senescence, and apoptosis(36). Disruption of p53 leads to
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altered regulation of each of these responses, which likely contributes to resistance
to radiation therapy in tumor cells(78). Additionally, expression of mutant p53 can
have gain-of-function activity, which has been reported to increase genetic
instability and alter the response to DNA damage(79, 80). Preclinical evaluation of
TP53 mutations and the response of HNSCC cells to radiation have led to mixed
conclusions(81), and remains to be further elucidated.
Another interesting observation is the association of TP53 point and
disruptive mutations with the development of DM in our study. Among the largest
studies to evaluate TP53 in HNSCC, several have found an association between
specific TP53 mutations and OS and DFS in HNSCC(45, 57, 61), but only one study
examined DM, specifically(44). Koch, et al. did record DM in their report, but the
proportions of patients who developed DM in the TP53 wildtype and the TP53
mutant groups were roughly equivalent, and no further evaluation regarding DM
was reported.

Two notable preclinical studies have described metastasis as a

potential gain-of-function property of the of R172H-TP53 mutation in in vivo ‘knockin’ mouse models of cutaneous(82) and pancreatic cancers(83). In our patient set,
we have identified an association of TP53 point mutations and disruptive mutations
with the development of DM.

Whether gain-of-function TP53 mutations are

contributing to metastasis in HNSCC remains to be elucidated.
A potential flaw of our study is that 8 patients (11%) had oropharyngeal
cancer, and the HPV status of these tumors is not known. Notably, only 5 of these
patients retained wildtype TP53. Five of the oropharyngeal cancer patients had no
evidence of disease at last follow up, and two of these patients who did not recur
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had tumors with mutations in TP53. Thus, there may have been HPV positive
tumors among our patient set, however the impact these patients may have had on
the survival outcomes evaluated in our study is likely negligible. This is in contrast
to previous reports linking TP53 mutation to poor outcome, in which substantial
numbers of patients with oropharyngeal cancer were evaluated(45, 57, 61). The
study by Lindenbergh, et al.(61) did evaluate HPV DNA and E6/E7 expression,
identifying HPV-related disease in 12 cases.

The cohort in this study were all

treated with surgery or surgery and radiotherapy. As primary surgery is not the
standard recommendation for oropharyngeal cancer in the large majority of centers
in the United States, it is difficult to interpret the results regarding the 43 patients
with oropharyngeal cancer that were evaluated in this study. TP53 mutations in
patients with HPV-negative oropharyngeal squamous cell carcinoma have been
evaluated by Fallai, et al., and disruptive TP53 mutation did not appear to be
associated with poor outcome in this study (64), however further evaluation of this
patient population is necessary.
The evidence to date has supported TP53 as a potentially useful marker in
the management of HNSCC. If TP53 sequencing is to become part of the routine
diagnostic regimen, the question arises as to what methodology would best identify
TP53 mutations in tumor specimens when a patient is initially diagnosed with
HNSCC. Our pilot study of the TP53 AmpliChip® has demonstrated the utility of
this method. As the AmpliChip® identified mutations in 5 additional patients who
were called as wildtype with standard sequencing methods, it would appear that the
AmpliChip® is a more sensitive technique for identifying mutations, however
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additional testing of these samples with a third chemistry is necessary to determine
whether the results from the Sanger method or AmpliChip® are true in the
discordant cases. One could argue that the Sanger method would have been more
accurate if microdissection were performed on these samples, but the tumor volume
necessary to obtain adequate DNA for this technique would required timeconsuming microdissection of several slides given the small area of tumor present
in these samples. Typical biopsy samples are small, and often contaminated with a
significant amount of normal stroma or lymphoid tissue. Furthermore, initial biopsy
material is often formalin-fixed and paraffin embedded prior to ultimate referral to
the head and neck oncology team. Thus, the TP53 AmpliChip® appears to be a
superior method given the ease of processing from readily available materials, as
well as concerning the seemingly high accuracy of this method despite fixation and
embedding of the tissue and the ability to call mutations in a significant background
of wildtype contamination.
The AmpliChip® offers other potential applications, including TP53
sequencing from lymph node micrometastases, which often have a high degree of
contaminating normal surrounding lymphocytes and stroma, and sequencing from
fine needle aspiration samples. Testing of this method in these settings has not
been undertaken and is a potential area of further study.
One could argue that the additional mutations identified in this pilot study
represent false-positive mutation calls. This would seem unlikely given the identical
calls made in the 11 concordant samples, but a third chemistry

sequencing

analysis (4-5-4 sequencing) from the DNA isolated after microdissection is currently
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underway in order to determine if additional mutations called by AmpliChip® or the
Sanger method were true positive calls.

The fact that there was considerable

discrepancy between the two methodologies used to determine TP53 status in our
pilot study suggests that all studies that have examined TP53 in HNSCC should be
reviewed with some caution and skepticism.

Differing techniques in tissue

processing, variability and inaccuracy in pathologic review to determine percentage
of tumor, extent of microdissection, and methodologies used to detect TP53
mutations can each alter the proportion of false-negative TP53 mutation results, and
has surely contributed to the variation in conclusions drawn from the existing
literature studying TP53 in HNSCC. Our pilot study comparing the AmpliChip® and
standard sequencing highlights this fact, and further comparative studies between
TP53 mutation detection methods should be undertaken in order to arrive at a
consensus as to the best method to obtain the most reliable TP53 sequence results
in a cost-efficient manner.

Future Directions
In selecting patients with advanced, resectable disease who were treated
uniformly with surgery and PORT, we have isolated a patient subset that is in need
of new management options that improve outcome. We have shown that TP53
mutation can potentially be used as a marker to predict for a worse outcome and
the development of DM, and the presence of TP53 mutation in advanced,
resectable tumors may warrant escalated therapy. Validation of our findings and

45

those of others requires prospective evaluation of specific therapeutic interventions
of site- and stage-matched patients with and without TP53 mutations.

Current

studies of HNSCC at UTMDACC designed to examine TP53 mutation have opened,
and the author is aware of a recent European study that intends to stratify patients
by TP53 mutation and examine the response to induction therapy with a taxanebased regimen.
Our work with the TP53 AmpliChip® suggests that this is a promising method
that could be introduced into the clinical setting and be a powerful research tool that
allows rapid and reliable evaluation of TP53 from large sets of archived FFPE
samples. To further test this method, the author and supervisory professor have
initiated a large retrospective study utilizing the AmpliChip® to evaluate TP53 from
archived oral cavity squamous cell cancer specimens from patients treated at
institutions from several regions of the world.

The goal is to study both the

prevalence of TP53 mutations, and the association of TP53 mutation with outcome
in the setting of different risk-factors for this disease (eg. tobacco smoke vs. alcohol
use vs. betel quid use). TP53 AmpliChip® results will be validated in a subset of
these patients with 4-5-4 sequencing in order to establish the error rate of this
method in this patient population.

Conclusions
Patients with advanced, resectable HNSCC and point mutations in TP53,
particularly disruptive mutations, have a poor prognosis if treated with standard
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therapeutic approaches. Our findings need to be validated in prospective trials. If
so, novel treatment strategies targeting the primary mechanisms of treatment failure
must be developed. Consideration should be given to trials investigating the
efficacy of systemic-dose level chemotherapy, either as an induction or possibly an
adjuvant strategy, in an attempt to decrease the rate of distant disease recurrence
in this subgroup. As support for TP53 mutation analysis as a biomarker in the
management of HNSCC grows, there is a necessity for a reliable, rapid method of
TP53 mutation detection from available tissue. Our pilot study examining the
AmpliChip® p53 test demonstrates the potential advantages and applications of this
method, particularly for HNSCC.
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